|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2004
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N06AX21
|
|
gptkbp:bioavailability
|
50%
|
|
gptkbp:brand
|
gptkb:Cymbalta
Irenka
|
|
gptkbp:CASNumber
|
gptkb:136434-34-9
|
|
gptkbp:contraindication
|
gptkb:Uncontrolled_narrow-angle_glaucoma
Concomitant use with MAO inhibitors
|
|
gptkbp:drugInteraction
|
gptkb:beer
gptkb:MAO_inhibitors
CYP2D6 inhibitors
CYP1A2 inhibitors
|
|
gptkbp:eliminationHalfLife
|
12 hours
|
|
gptkbp:excretion
|
Urine
|
|
gptkbp:hasDrugBankCategory
|
Antidepressant
Serotonin and norepinephrine reuptake inhibitor
|
|
gptkbp:hasInChIKey
|
PTFQOBMPAATQMB-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
gptkb:C18H19NOS
|
|
gptkbp:hasReceptorTarget
|
gptkb:Serotonin_transporter
gptkb:Norepinephrine_transporter
|
|
gptkbp:hasSMILES
|
CN(C)CCOC1=CC=CC=C1C2=CC=CC=C2S
|
|
gptkbp:hasUNII
|
O5TNM5N07U
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB01452
|
|
gptkbp:indication
|
gptkb:Chronic_musculoskeletal_pain
gptkb:Diabetic_peripheral_neuropathic_pain
gptkb:Major_depressive_disorder
Fibromyalgia
Generalized anxiety disorder
|
|
gptkbp:legalStatus
|
Prescription only
Patent expired
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:mechanismOfAction
|
Inhibits reuptake of serotonin and norepinephrine
|
|
gptkbp:metabolism
|
gptkb:Hepatic_(CYP1A2,_CYP2D6)
|
|
gptkbp:molecularWeight
|
297.42
|
|
gptkbp:name
|
gptkb:Duloxetine
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:PubChem_CID
|
60835
CHEBI:36794
D07861
|
|
gptkbp:routeOfAdministration
|
gptkb:Oral
|
|
gptkbp:sideEffect
|
gptkb:Nausea
gptkb:Somnolence
Constipation
Dry mouth
Decreased appetite
|
|
gptkbp:synonym
|
gptkb:LY248686
|
|
gptkbp:bfsParent
|
gptkb:Heroin
|
|
gptkbp:bfsLayer
|
6
|